The FDA approved camizestrant for ESR1-mutated breast cancer, cleared ropeginterferon alfa-2b for essential thrombocythemia, and more.
News|Videos|March 7, 2025
The ARANOTE Phase 3 Trial of Darolutamide Plus Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer: Efficacy and Safety by Disease Volume
Author(s)Fred Saad, MD, FRCS
Dr. Fred Saad presents a post-hoc analysis of the Phase 3 ARANOTE trial, demonstrating that darolutamide plus androgen-deprivation therapy significantly improves radiographic progression-free survival and delays metastatic castration-resistant prostate cancer in patients with metastatic hormone-sensitive prostate cancer, with consistent efficacy across disease volume subgroups and a favorable safety profile.
Advertisement
Advertisement
Related to this article
Dana Chase, MD, discusses why B7-H4 has emerged as a promising antibody-drug conjugate target in ovarian and endometrial cancer.
The FDA approved camizestrant plus a CDK4/6 inhibitor for hormone receptor–positive, HER2-negative metastatic breast cancer that acquires an ESR1 mutation.
Brain cancer experts explain the current wave of surgical advances and advocate for team-based, multidisciplinary strategies to individualize patient care.
Huntsman Cancer Institute at the University of Utah celebrated a major milestone in the development of Huntsman Cancer Institute in Vineyard.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
A new life-years-saved methodology found blood cancer treatments saved million years of life since 1949, with future gains reliant on funding and access.
Tycel Phillips, MD, discusses sonrotoclax’s FDA approval for mantle cell lymphoma and why the BCL2 inhibitor opens more possibilities.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
2
B7-H4–Targeted ADCs Signal a New Frontier for Platinum-Resistant Ovarian and Endometrial Cancer
3
Brachytherapy and Minimally Invasive Surgical Techniques Signal the Future of Brain Cancer Management
4
Novel Analysis Reveals Millions of Life-Years Saved by Blood Cancer Treatments
5